Form 10-Q REATA PHARMACEUTICALS For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Reata Pharma (RETA) Tops Q3 EPS by 10c
November 14, 2016 8:35 AM ESTReata Pharma (NASDAQ: RETA) reported Q3 EPS of ($0.04), $0.10 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $12.55 million versus the consensus estimate of $12.46 million.
For earnings history and earnings-related data on Reata Pharma (RETA) click here.
... More